Bortezomib as the Sole Post-Renal Transplantation Desensitization Agent Does Not Decrease Donor-Specific Anti-HLA Antibodies

被引:99
作者
Sberro-Soussan, R. [1 ,2 ]
Zuber, J. [1 ,2 ]
Suberbielle-Boissel, C. [3 ]
Candon, S. [1 ,4 ]
Martinez, F. [2 ]
Snanoudj, R. [2 ]
Rabant, M. [1 ,2 ]
Pallet, N. [1 ,2 ]
Nochy, D. [5 ]
Anglicheau, D. [1 ,2 ]
Leruez, M. [1 ,6 ]
Loupy, A. [1 ,2 ]
Thervet, E. [1 ,2 ]
Hermine, O. [1 ,7 ]
Legendre, C. [1 ,2 ]
机构
[1] Univ Paris 05, Paris, France
[2] Hop Necker Enfants Malad, AP HP, Serv Transplantat Renale, Paris, France
[3] Hop St Louis, AP HP, Lab Histocompatibil, Paris, France
[4] Hop Necker Enfants Malad, AP HP, Immunol Lab, Paris, France
[5] Hop Europeen Georges Pompidou, AP HP, Lab Anatomopathol, Paris, France
[6] Hop Necker Enfants Malad, AP HP, Virol Lab, Paris, France
[7] Hop Necker Enfants Malad, AP HP, Serv Hematol Clin Adulte, Paris, France
关键词
Bortezomib; desensitize; donor-specific antibodies; DSA; kidney transplantation; HIGH-DOSE DEXAMETHASONE; CROSS-MATCH; INTRAVENOUS IMMUNOGLOBULIN; MEDIATED REJECTION; PLASMA-CELLS; INHIBITOR; DISEASE;
D O I
10.1111/j.1600-6143.2009.02968.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Persistence of donor-specific anti-HLA antibodies (DSA) associated with antibody-mediated graft injuries following kidney transplantation predicts evolution toward chronic humoral rejection and reduced graft survival. Targeting plasma cells, the main antibody-producing cells, with the proteasome inhibitor bortezomib may be a promising desensitization strategy. We evaluated the in vivo efficacy of one cycle of bortezomib (1.3 mg/m2 x 4 doses), used as the sole desensitization therapy, in four renal transplant recipients experiencing subacute antibody-mediated rejection with persisting DSA (> 2000 [Mean Fluorescence Intensity] MFI). Bortezomib treatment did not significantly decrease DSA MFI within the 150-day posttreatment period in any patient. In addition, antivirus (HBV, VZV and HSV) antibody levels remained stable following treatment suggesting a lack of efficacy on long-lived plasma cells. In conclusion, one cycle of bortezomib alone does not decrease DSA levels in sensitized kidney transplant recipients in the time period studied. These results underscore the need to evaluate this new desensitization agent properly in prospective, randomized and well-controlled studies.
引用
收藏
页码:681 / 686
页数:6
相关论文
共 21 条
[11]   Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition [J].
Meister, Silke ;
Schubert, Ulrich ;
Neubert, Krsten ;
Herrmann, Kai ;
Burger, Renate ;
Gramatzki, Martin ;
Hahn, Sabine ;
Schreiber, Sandra ;
Wilhelm, Sabine ;
Herrmann, Martin ;
Jaeck, Hans-Martin ;
Voll, Reinhard E. .
CANCER RESEARCH, 2007, 67 (04) :1783-1792
[12]   Transplanting patients with a positive donor-specific crossmatch: A single center's perspective [J].
Montgomery, RA ;
Zachary, AA .
PEDIATRIC TRANSPLANTATION, 2004, 8 (06) :535-542
[13]   The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis [J].
Neubert, Kirsten ;
Meister, Silke ;
Moser, Katrin ;
Weisel, Florian ;
Maseda, Damian ;
Amann, Kerstin ;
Wiethe, Carsten ;
Winkler, Thomas H. ;
Kalden, Joachim R. ;
Manz, Rudolf A. ;
Voll, Reinhard E. .
NATURE MEDICINE, 2008, 14 (07) :748-755
[14]   Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production [J].
Perry, D. K. ;
Burns, J. M. ;
Pollinger, H. S. ;
Amiot, B. P. ;
Gloor, J. M. ;
Gores, G. J. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (01) :201-209
[15]   Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG [J].
Perrya, D. K. ;
Pollinger, H. S. ;
Burns, J. M. ;
Rea, D. ;
Ramos, E. ;
Platt, J. L. ;
Gloor, J. M. ;
Stegall, M. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (01) :133-143
[16]   The effect of desensitization protocols on human splenic B-cell populations in vivo [J].
Ramos, E. J. ;
Pollinger, H. S. ;
Stegall, M. D. ;
Gloor, J. M. ;
Dogan, A. ;
Grande, J. P. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (02) :402-407
[17]   Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].
Richardson, PG ;
Sonneveld, P ;
Schuster, MW ;
Irwin, D ;
Stadtmauer, EA ;
Facon, T ;
Harousseau, JL ;
Ben-Yehuda, D ;
Lonial, S ;
Goldschmidt, H ;
Reece, D ;
San-Miguel, JF ;
Bladé, J ;
Boccadoro, M ;
Cavenagh, J ;
Dalton, WS ;
Boral, AL ;
Esseltine, DL ;
Porter, JB ;
Schenkein, D ;
Anderson, KC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498
[18]   Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors [J].
Shah, MH ;
Young, D ;
Kindler, HL ;
Webb, I ;
Kleiber, B ;
Wright, J ;
Grever, M .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6111-6118
[19]   Banff '05 Meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') [J].
Solez, K. ;
Colvin, R. B. ;
Racusen, L. C. ;
Sis, B. ;
Halloran, P. F. ;
Birk, P. E. ;
Campbell, P. M. ;
Cascalho, M. ;
Collins, A. B. ;
Demetris, A. J. ;
Drachenberg, C. B. ;
Gibson, I. W. ;
Grimm, P. C. ;
Haas, M. ;
Lerut, E. ;
Liapis, H. ;
Mannon, R. B. ;
Marcus, P. B. ;
Mengel, M. ;
Mihatsch, M. J. ;
Nankivell, B. J. ;
Nickeleit, V. ;
Papadimitriou, J. C. ;
Platt, J. L. ;
Randhawa, P. ;
Roberts, I. ;
Salinas-Madriga, L. ;
Salomon, D. R. ;
Seron, D. ;
Sheaff, M. ;
Weening, J. J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (03) :518-526
[20]   Abrogation of Anti-HLA Antibodies via Proteasome Inhibition [J].
Trivedi, Hargovind L. ;
Terasaki, Paul I. ;
Feroz, Aziz ;
Everly, Matthew J. ;
Vanikar, Aruna V. ;
Shankar, Vangipurapu ;
Trivedi, Varsha B. ;
Kaneku, Hugo ;
Idica, Adam K. ;
Modi, Pranjal R. ;
Khemchandani, Sajani I. ;
Dave, Shruti D. .
TRANSPLANTATION, 2009, 87 (10) :1555-1561